![Jérôme Tiollier](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jérôme Tiollier
Gründer bei Jalon Therapeutics
Aktive Positionen von Jérôme Tiollier
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Jalon Therapeutics
![]() Jalon Therapeutics Pharmaceuticals: MajorHealth Technology Jalon Therapeutics is a French company that aims to develop innovative therapies to treat cancer by inactivating vital tumor signaling pathways. Jalon Therapeutics is based in Paris, France and manages an extensive candidate portfolio of drug candidates infused by its unique expertise in AAC-11 biology. The company leverages their deep understanding of stress-related protein-protein interaction networks that sustain the malignant phenotype while not being necessary for normal cells. The company's lead candidate, JRT39, is the first-in-class drug developed for the treatment of hard-to-treat cancers. The company is building a drug discovery platform to develop other candidates derived from AAC-11 and AAC-11 partners for the treatment of cancer. Jalon Therapeutics raised a pre-seed in 2022, leveraged by non-dilutive and quasi-equity fundings from public institutions. The company's growth ambition is to raise a seed immediately followed by a series A to finance up to the clinical proof of concept of their lead candidate JRT39. The company was founded in 2021 by Jérôme Tiollier, Jean-Luc Poyet, Prof. Martine Bagot, Prof. Hervé Dombret, Jean-Christophe Rain, and Philippe Salphati. The CEO is David Loison. | Vorsitzender | - | - |
Gründer | - | - |
Karriereverlauf von Jérôme Tiollier
Ehemalige bekannte Positionen von Jérôme Tiollier
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
INNATE PHARMA | Corporate Officer/Principal | 01.09.2001 | - |
Ausbildung von Jérôme Tiollier
University of Lyon | Undergraduate Degree |
Statistik
International
Frankreich | 4 |
Operativ
Corporate Officer/Principal | 1 |
Undergraduate Degree | 1 |
Chairman | 1 |
Sektoral
Health Technology | 3 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
INNATE PHARMA | Health Technology |
Private Unternehmen | 1 |
---|---|
Jalon Therapeutics
![]() Jalon Therapeutics Pharmaceuticals: MajorHealth Technology Jalon Therapeutics is a French company that aims to develop innovative therapies to treat cancer by inactivating vital tumor signaling pathways. Jalon Therapeutics is based in Paris, France and manages an extensive candidate portfolio of drug candidates infused by its unique expertise in AAC-11 biology. The company leverages their deep understanding of stress-related protein-protein interaction networks that sustain the malignant phenotype while not being necessary for normal cells. The company's lead candidate, JRT39, is the first-in-class drug developed for the treatment of hard-to-treat cancers. The company is building a drug discovery platform to develop other candidates derived from AAC-11 and AAC-11 partners for the treatment of cancer. Jalon Therapeutics raised a pre-seed in 2022, leveraged by non-dilutive and quasi-equity fundings from public institutions. The company's growth ambition is to raise a seed immediately followed by a series A to finance up to the clinical proof of concept of their lead candidate JRT39. The company was founded in 2021 by Jérôme Tiollier, Jean-Luc Poyet, Prof. Martine Bagot, Prof. Hervé Dombret, Jean-Christophe Rain, and Philippe Salphati. The CEO is David Loison. | Health Technology |
- Börse
- Insiders
- Jérôme Tiollier
- Erfahrung